NPM1 and malignant colon neoplasm: In order to investigate the role of nucleophosmin and its interaction partner c-Myc in the response and development of acquired resistance to BRAFV600E inhibition by vemurafenib (PLX4032), we measured the expression levels of NPM1, c-Myc and their phosphorylated forms p-NPM1 (Thr199) and p-c-Myc (Ser62) in sensitive colon cancer cell lines HT-29 and RKO and their vemurafenib-resistant counterparts HT-29r and RKOr, respectively, after exposure to cytotoxic concentrations (IC50) of PLX4032 (Supplementary Table S5) for 24, 48 and 72 h.